Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: persons (493), folks (1)

Registering New Studies into the CRF

Description: SCBR University Hospitals Southampton NHS Foundation Trust Standard Operating Procedure for Accepting Registering New Projects Studies into the Southampton NIHR Wellcome
Url: /Media/Southampton-Clinical-Research/CRF-templates/Registering-New-Studies-into-the-CRF.docx

NHS continuing healthcare: Fast track pathway - patient information

Description: This factsheet explains what NHS continuing healthcare (CHC) fast track funding is and what the fast track pathway involves so that
Url: /Media/UHS-website-2019/Patientinformation/Visitinghospital/NHS-continuing-healthcare-Fast-track-pathway-3947-PIL.pdf

EC-PPH Cyclophosphamide Epirubicin Paclitaxel Pertuzumab Trastuzumab

Description: Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-EPIRUBICIN-PACLITAXEL-PERTUZUMABTRASTUZUMAB (EC-PPH) Regimen • Breast Cancer – Cyclophosphamide-Epirubicin-Paclitaxel-PertuzumabTrastuzumab (EC-PPH) Indication • Neo
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/EC-PPH-Cyclophosphamide-Epirubicin-Paclitaxel-Pertuzumab-Trastuzumab.pdf

EC-DPH IV (Cyclophosphamide-Epirubicin-Docetaxel-Pertuzumab-Trastuzumab IV)

Description: Please refer to the most up to date Bluteq eligibility criteria for pertuzumab and trastuzumab before prescribing.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/EC-DPH-IV-Cyclophosphamide-Epirubicin-Docetaxel-Pertuzumab-Trastuzumab-IV.pdf

Annex B to guidance notes - Manager's Statement cohort 5

Description: Annex B Manager It is intended that this Section (Annex B) be sent with the guidance notes to your Manager fo
Url: /Media/Southampton-Clinical-Research/Downloads/Annex-B-to-guidance-notes-Managers-Statement-cohort-5.docx

Carboplatin

Description: Chemotherapy Protocol LUNG CANCER – SMALL CELL (SCLC) CARBOPLATIN (AUC6) 6 CYCLES Regimen  SCLC - Carboplatin (AUC6) 6 Cycle
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Carboplatin.pdf

EC-DPH SC (Cyclophosphamide-Epirubicin-Docetaxel-Pertuzumab+Trastuzumab SC)

Description: Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-EPIRUBICIN-DOCETAXEL-PERTUZUMAB / TRASTUZUMAB SC (EC-DPH SC) Regimen  Breast Can
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/EC-DPH-SC-Cyclophosphamide-Epirubicin-Docetaxel-PertuzumabTrastuzumab-SC.pdf

MyelomaBortezomib IV DexamethasonePabinostatThalidomide 21day Ver1.1

Description: Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (IV)-DEXAMETHASONE-PANOBINOSTAT-THALIDOMIDE Regimen (21 day) • Multiple Myeloma – Bortezomib (IV)-Dexamethasone-Panobinostat-Thalidomide (21 day
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-IV-DexamethasonePabinostatThalidomide-21day-Ver1.1.pdf

Aria ePrescribing v13.6 MR1.2 user training guide

Description: Aria E-Prescribing v13.6 MR1.2 User Training Guide Every effort has been made to ensure that the material in this manual was correct
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/User-guides/Aria-ePrescribing-v13.6-MR1.2-user-training-guide.pdf

Cyclophosphamide-Etoposide PO Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-ETOPOSIDE ORAL Regimen Lymphoma – Cyclophosphamide-Etoposide PO Indication Palliative treatment of malignant lymphoma Toxicity Drug Adverse Effect
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Cyclophosphamide-Etoposide-PO-Ver-1.1.pdf

161 to 170 of 699

Previous … 15 16 17 18 19 … Next